Pheochromocytoma

Bibliography

  1. Al Subhi, Abdul Rahman, Veronica Boyle, and Marianne S. Elston. "Systematic Review: Incidence of Pheochromocytoma and Paraganglioma Over 70 Years." Journal of the Endocrine Society 6, no. 9 (September 1, 2022): bvac105. https://doi.org/10.1210/jendso/bvac105.
  2. De Filpo, G., G. Cantini, G. Rastrelli, G. Vannini, T. Ercolino, M. Luconi, M. Mannelli, M. Maggi, and L. Canu. "Management and Outcome of Metastatic Pheochromocytomas/Paragangliomas: A Monocentric Experience." Journal of Endocrinological Investigation 45, no. 1 (January 1, 2022): 149–57. https://doi.org/10.1007/s40618-021-01629-x.
  3. Else, Tobias. "15 YEARS OF PARAGANGLIOMA: Pheochromocytoma, Paraganglioma and Genetic Syndromes: A Historical Perspective." Endocrine-Related Cancer 22, no. 4 (August 1, 2015): T147–59. https://doi.org/10.1530/ERC-15-0221.
  4. Fassnacht, M., G. Assie, E. Baudin, G. Eisenhofer, C. de la Fouchardiere, H. R. Haak, R. de Krijger, F. Porpiglia, M. Terzolo, and A. Berruti. "Adrenocortical Carcinomas and Malignant Phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up†." Annals of Oncology 31, no. 11 (November 1, 2020): 1476–90. https://doi.org/10.1016/j.annonc.2020.08.2099.
  5. Fishbein, Lauren, Jaydira Del Rivero, Tobias Else, James R. Howe, Sylvia L. Asa, Debbie L. Cohen, Patricia L. M. Dahia, et al. "The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma." Pancreas 50, no. 4 (April 2021): 469–93. https://doi.org/10.1097/MPA.0000000000001792.
  6. Garcia-Carbonero, R., F. Matute Teresa, E. Mercader-Cidoncha, M. Mitjavila-Casanovas, M. Robledo, I. Tena, C. Alvarez-Escola, et al. "Multidisciplinary Practice Guidelines for the Diagnosis, Genetic Counseling and Treatment of Pheochromocytomas and Paragangliomas." Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 23, no. 10 (October 2021): 1995–2019. https://doi.org/10.1007/s12094-021-02622-9.
  7. Hamidi, Oksana. "Metastatic Pheochromocytoma and Paraganglioma: Recent Advances in Prognosis and Management." Current Opinion in Endocrinology, Diabetes & Obesity 26, no. 3 (June 2019): 146–54. https://doi.org/10.1097/MED.0000000000000476.
  8. Hescot, Segolene, Maria Curras-Freixes, Timo Deutschbein, Anouk van Berkel, Delphine Vezzosi, Laurence Amar, Christelle de la Fouchardière, et al. "Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study." The Journal of Clinical Endocrinology & Metabolism 104, no. 6 (June 1, 2019): 2367–74. https://doi.org/10.1210/jc.2018-01968.
  9. Kim, Jung Hee, Hyemi Moon, Junghyun Noh, Juneyoung Lee, and Sin Gon Kim. "Epidemiology and Prognosis of Pheochromocytoma/Paraganglioma in Korea: A Nationwide Study Based on the National Health Insurance Service." Endocrinology and Metabolism (Seoul, Korea) 35, no. 1 (March 2020): 157–64. https://doi.org/10.3803/EnM.2020.35.1.157.
  10. Nölting, Svenja, Nicole Bechmann, David Taieb, Felix Beuschlein, Martin Fassnacht, Matthias Kroiss, Graeme Eisenhofer, Ashley Grossman, and Karel Pacak. "Personalized Management of Pheochromocytoma and Paraganglioma." Endocrine Reviews 43, no. 2 (March 9, 2022): 199–239. https://doi.org/10.1210/endrev/bnab019.
14 / 14